2.2020
-0.0420
(-1.87%)
At close: January 24 at 8:02:39 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
169,879.0000
194,623.0000
292,484.0000
211,650.0000
294,644.0000
Cost of Revenue
61,477.0000
74,149.0000
85,568.0000
150,671.0000
296,477.0000
Gross Profit
108,402.0000
120,474.0000
206,916.0000
60,979.0000
-1,833.0000
Operating Expense
143,135.0000
166,549.0000
271,762.0000
325,481.0000
375,993.0000
Operating Income
-34,733.0000
-46,075.0000
-64,846.0000
-264,502.0000
-377,826.0000
Net Non Operating Interest Income Expense
-12,726.0000
-6,032.0000
-15,687.0000
-19,936.0000
-8,871.0000
Other Income Expense
1,467.0000
182.0000
-13,693.0000
2,414.0000
1,856.0000
Pretax Income
-45,992.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
Net Income Common Stockholders
-45,992.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
Diluted NI Available to Com Stockholders
-45,992.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
Basic EPS
-0.22
-0.28
-0.51
-1.70
-2.77
Diluted EPS
-0.22
-0.28
-0.51
-1.70
-2.77
Basic Average Shares
203,740.2990
187,465.4480
182,782.6800
165,949.6950
138,463.1520
Diluted Average Shares
203,740.2990
187,465.4480
182,782.6800
165,949.6950
138,463.1520
Total Operating Income as Reported
-34,791.0000
-46,256.0000
-80,779.0000
-264,502.0000
-377,826.0000
Total Expenses
204,612.0000
240,698.0000
357,330.0000
476,152.0000
672,470.0000
Net Income from Continuing & Discontinued Operation
-45,992.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
Normalized Income
-46,762.0000
-51,220.0000
-77,387.0000
-282,024.0000
-384,841.0000
Interest Income
3,319.0000
--
--
--
--
Interest Expense
12,726.0000
6,032.0000
15,687.0000
19,936.0000
8,871.0000
Net Interest Income
-12,726.0000
-6,032.0000
-15,687.0000
-19,936.0000
-8,871.0000
EBIT
-33,266.0000
-45,893.0000
-78,539.0000
-264,502.0000
-377,826.0000
EBITDA
4,297.0000
-8,266.0000
-40,842.0000
-226,532.0000
-343,134.0000
Reconciled Cost of Revenue
61,477.0000
74,149.0000
85,568.0000
150,671.0000
296,477.0000
Reconciled Depreciation
37,563.0000
37,627.0000
37,697.0000
37,970.0000
34,692.0000
Net Income from Continuing Operation Net Minority Interest
-45,992.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
Total Unusual Items Excluding Goodwill
770.0000
-705.0000
-16,839.0000
--
--
Total Unusual Items
770.0000
-705.0000
-16,839.0000
--
--
Normalized EBITDA
3,527.0000
-7,561.0000
-24,003.0000
-226,532.0000
-343,134.0000
12/31/2020 - 4/1/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DPM.F Sumitomo Pharma Co., Ltd.
3.5000
+4.17%
TRA.VN Traphaco Joint Stock Company
76,900.00
0.00%
526075.BO 526075.BO,0P0000BXCE,0
4.5000
0.00%
NECLIFE.BO Nectar Lifesciences Limited
38.57
-1.98%
R9U2.F Green Thumb Industries Inc.
6.67
-0.67%
BON.SG Boiron SA
25.20
-3.63%
STSN Stemsation International, Inc.
0.0060
-1.64%
RAPH Raphael Pharmaceutical Inc.
1.0000
0.00%
APPH.DE Apontis Pharma AG
10.40
+1.96%
SHE.MI Shedir Pharma Group S.p.A.
4.8800
0.00%